We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Status: Active

Mar 25th 2021 - Apr 12th 2021

MunchFit aims to provide fitness enthusiasts with nutritious and goal-based meals to support their training goal. The company has served over 450,000 goal-based meals via retailers, cafés, and e-commerce channels. It claims that its meals are assessed by Mark Ellison, nutritionist for Anthony Joshua and Manchester United FC. The company has also signed partnerships with Planet Organic and Ocado, stocking its products in the former and at its fitness cafés at Equinox. MunchFit asserts that it responded to the COVID-19 pandemic by launching MunchFit Meal Plans coupled with a nationwide delivery scheme. The company points out that this led to it achieving a weekly average run rate of £15,000, nearly double the £7,600 run rate it had witnessed six months prior. MunchFit will use the investment to grow its meal plans, invest in product development and key hires, launch five new café sites, and target major supermarkets with its 'Fuel' range as a retail product.

read more read less
Log in to view amount pledged

    Log in to view target

    £5,001,311
    pre-money valuation

    13.04%
    equity available

    330
    investors

    £3,636
    pledge per investor

    08655512
    company number

    Liquidation
    company status

    19/08/2013
    incorporated 11 years

    £1.80
    share price

    Previous Funding rounds
    09 Apr 24 Crowdcube £1,200,009 / 160%

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld

Log in to view amount pledged

    Log in to view target

    £5,001,311
    pre-money valuation

    13.04%
    equity available

    330
    investors

    £3,636
    pledge per investor

    08655512
    company number

    Liquidation
    company status

    19/08/2013
    incorporated 11 years

    £1.80
    share price

    Previous Funding rounds
    09 Apr 24 Crowdcube £1,200,009 / 160%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph